Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
H. Lundbeck A/S
Acquired Company
Xeris Biopharma Holdings
Copenhagen
ChicagoBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareBiopharmaDescription
H Lundbeck is exploring an acquisition of Xeris Biopharma, causing a 6% spike in Xeris's stock. Despite Xeris’s insistence that it is not for sale, the interest highlights Lundbeck's recognition of strategic value in Xeris's pipeline. This potential acquisition points towards the increasing significance of chronic endocrine and neurological therapies in the pharmaceutical market.
Fundz sees it the moment H. Lundbeck A/S makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Xeris Biopharma Holdings?
Xeris Biopharma Holdings was acquired by H. Lundbeck A/S, based in Copenhagen. The deal was reported on September 29, 2026. H. Lundbeck A/S is a pharmaceutical company specializing in the research, development, production, marketing, and sale of drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is privately held and operates in Biotechnology.
When did H. Lundbeck A/S acquire Xeris Biopharma Holdings?
H. Lundbeck A/S's acquisition of Xeris Biopharma Holdings was reported on September 29, 2026. H Lundbeck is exploring an acquisition of Xeris Biopharma, causing a 6% spike in Xeris's stock. Despite Xeris’s insistence that it is not for sale, the interest highlights Lundbeck's recognition of strategic value in Xeris's pipeline. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Xeris Biopharma Holdings do?
Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. It is publicly traded (XERS), operating in Biotechnology, and is based in Chicago.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.